Market-based licensing for HPV vaccines in developing countries
- PMID: 18180488
- DOI: 10.1377/hlthaff.27.1.130
Market-based licensing for HPV vaccines in developing countries
Abstract
Human papillomavirus (HPV) vaccines hold great promise for preventing cervical cancer, but 93 percent of mortality worldwide occurs in low- and middle-income countries, where high vaccine costs can restrict dissemination. Current models for promoting international access to health care innovations include differential pricing, advance market commitments, and voluntary and compulsory licensing. Some of these mechanisms have been effective, but much room for improvement remains. We discuss the usefulness of a new type of license that uses market forces to lower prices through generic competition in low- and middle-income countries while ensuring that pharmaceutical companies are appropriately reimbursed for their research and development.
Similar articles
-
The GO License: only part of the solution.Health Aff (Millwood). 2008 Jan-Feb;27(1):140-2. doi: 10.1377/hlthaff.27.1.140. Health Aff (Millwood). 2008. PMID: 18180489
-
Differential pricing for pharmaceuticals: reconciling access, R&D and patents.Int J Health Care Finance Econ. 2003 Sep;3(3):183-205. doi: 10.1023/a:1025384819575. Int J Health Care Finance Econ. 2003. PMID: 14625999 Review.
-
Compulsory licenses: a tool to improve global access to the HPV vaccine?Am J Law Med. 2009;35(2-3):323-50. doi: 10.1177/009885880903500205. Am J Law Med. 2009. PMID: 19697752
-
Vaccines as a global imperative--a business perspective.Health Aff (Millwood). 2011 Jun;30(6):1042-8. doi: 10.1377/hlthaff.2011.0338. Health Aff (Millwood). 2011. PMID: 21653955
-
Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.Vaccine. 2006 Aug 31;24 Suppl 3:S3/219-25. doi: 10.1016/j.vaccine.2006.05.042. Epub 2006 Jun 6. Vaccine. 2006. PMID: 16950010 Review.
Cited by
-
Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways.Am J Public Health. 2014 Nov;104(11):e85-91. doi: 10.2105/AJPH.2014.302236. Epub 2014 Sep 11. Am J Public Health. 2014. PMID: 25211753 Free PMC article.
-
Challenges for nationwide vaccine delivery in African countries.Int J Health Econ Manag. 2018 Jun;18(2):197-219. doi: 10.1007/s10754-017-9229-5. Epub 2017 Oct 19. Int J Health Econ Manag. 2018. PMID: 29047019 Review.
-
Introducing HPV Vaccine in Developing Countries - Addressing the Challenge.Indian J Community Med. 2009 Oct;34(4):370-1. doi: 10.4103/0970-0218.58407. Indian J Community Med. 2009. PMID: 20165642 Free PMC article. No abstract available.
-
Rethinking global access to vaccines.BMJ. 2008 Apr 5;336(7647):750-3. doi: 10.1136/bmj.39497.598044.BE. BMJ. 2008. PMID: 18390526 Free PMC article.
-
Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India.Nat Biotechnol. 2010 Jul;28(7):671-8. doi: 10.1038/nbt0710-671. Nat Biotechnol. 2010. PMID: 20622834 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
